These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26676909)

  • 1. Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.
    McDougall DA; Martin J; Playford EG; Green B
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):165-77. PubMed ID: 26676909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Model-Misspecification on Model Based Personalised Dosing.
    McDougall DAJ; Martin J; Playford EG; Green B
    AAPS J; 2016 Sep; 18(5):1244-1253. PubMed ID: 27306545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.
    Kluwe F; Michelet R; Huisinga W; Zeitlinger M; Mikus G; Kloft C
    Clin Pharmacokinet; 2023 Oct; 62(10):1461-1477. PubMed ID: 37603216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.
    Farkas A; Daroczi G; Villasurda P; Dolton M; Nakagaki M; Roberts JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6806-6812. PubMed ID: 27600031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
    Muto C; Shoji S; Tomono Y; Liu P
    Antimicrob Agents Chemother; 2015; 59(6):3216-23. PubMed ID: 25801557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
    Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
    Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalised dosing of medicines for children.
    Al-Metwali B; Mulla H
    J Pharm Pharmacol; 2017 May; 69(5):514-524. PubMed ID: 28266713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization.
    Chantharit P; Tantasawat M; Kasai H; Tanigawara Y
    Ther Drug Monit; 2020 Dec; 42(6):872-879. PubMed ID: 32947557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children.
    Zane NR; Thakker DR
    Clin Pharmacokinet; 2014 Dec; 53(12):1171-82. PubMed ID: 25245942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.
    Kim HY; Märtson AG; Dreesen E; Spriet I; Wicha SG; McLachlan AJ; Alffenaar JW
    Front Pharmacol; 2020; 11():894. PubMed ID: 32595511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
    Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
    Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.
    Huang W; Zheng Y; Huang H; Cheng Y; Liu M; Chaphekar N; Wu X
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1447-1457. PubMed ID: 35764817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
    Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
    Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.